 BETHLEHEM, Pa., Sept. 23, 2021 GLOBE NEWSWIRE -- OraSure Technologies, Inc. NASDAQ: OSUR, a global leader in point-of-care and home diagnostic testing and sample collection technologies, announced today that the Biomedical Advanced Research Development Authority BARDA, part of the office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services HHS, will provide up to 13.6 million in funding for the Company to obtain 510k clearance and Clinical Laboratory Improvement Amendments CLIA waiver for OraSures InteliSwabTM COVID-19 rapid test from the Food and Drug Administration FDA. 